Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;25(10):1513-31.
doi: 10.1016/j.euroneuro.2015.06.009. Epub 2015 Jun 20.

Unmet Needs in Paediatric Psychopharmacology: Present Scenario and Future Perspectives

Affiliations
Review

Unmet Needs in Paediatric Psychopharmacology: Present Scenario and Future Perspectives

Antonio M Persico et al. Eur Neuropsychopharmacol. .

Abstract

Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development. Priorities and strategies are proposed to overcome some of these limitations, including the European Child and Adolescent Clinical Psychopharmacology Network, as an overarching Pan-European infrastructure aimed at reliably carrying out much needed psychopharmacological trials in children and adolescents, in order to fill the identified gaps and improve overall outcomes.

Keywords: Autism spectrum disorder; Biomarkers; Intellectual disability; Off-label use; Pharmaceutical policies; Psychopharmacology.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

Publication types

Substances

Feedback